Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

New developments in the management of COPD: clinical utility of indacaterol 75 µg

Authors Steiropoulos P, Archontogeorgis K, Nena E, Bouros D

Received 19 August 2013

Accepted for publication 16 October 2013

Published 6 December 2013 Volume 2014:9(1) Pages 1—7


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Paschalis Steiropoulos,1 Kostas Archontogeorgis,1 Evangelia Nena,2 Demosthenes Bouros1

1Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece; 2Laboratory of Hygiene and Environmental Protection, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

Abstract: Chronic obstructive pulmonary disease (COPD) is a global health challenge and a major cause of mortality worldwide. Bronchodilators, particularly long-acting β2-agonists and long-acting antimuscarinic agents, used singly or in combination, aim to improve lung function, reduce symptoms, prevent exacerbations, and enhance quality of life of COPD patients. Indacaterol is a novel, inhaled, long-acting β2-agonist, with rapid onset of action and once-daily dosing providing 24-hour bronchodilation. Currently, the recommended dose differs between Europe (150 µg; maximum 300 µg) and USA (75 µg), the latter is lower than that assessed in the majority of the conducted studies. This review summarises published evidence regarding the efficacy, tolerability, and safety of indacaterol at a dose of 75 µg. Indacaterol 75 µg was found to be superior than placebo regarding lung function, dyspnea, health status, use of rescue medication, and rate of exacerbations. Furthermore, indacaterol 75 µg was well tolerated, while the most frequent adverse effect was deterioration of COPD occurring at a frequency similar to placebo, without major cardiovascular adverse effects. In conclusion, indacaterol 75 µg, administered once daily, is efficacious and has an excellent tolerability and safety profile, and is therefore a valid alternative in the treatment of COPD patients.

Keywords: chronic obstructive pulmonary disease, long-acting bronchodilators, β2-agonists, indacaterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]